Acrux History

ACRUX TIMELINE

1998

Acrux incorporated

2001

First US patent granted

2003

Veterinary licensed to Elanco globally (including Recuvyra®)

2004

Acrux listed on ASX (ACR:ASX)

2007

Evamist® licensed to KV Pharmaceutical in US

2008

Evamist® launched by KV Pharmaceutical

Acrux initiates Axiron® Phase III clinical trial

2010

Acrux submits Axiron® NDA to FDA

Axiron® licensed to Eli Lilly globally

2011

Axiron® launched by Eli Lilly

2013

Recuvyra® launched by Elanco

Estradiol licensed to Gedeon Richter; including for EU

2014

Evamist® licensed to Perrigo in US

2015

Initiated generic programs

2016

Lenzetto® launched in Europe

2017

Active pipeline of 10 generic products